Citi analyst Daniel Grosslight initiated coverage of GoodRx with a Buy rating and $7 price target. "In a rational healthcare market," GoodRx would not exist, but the "irrationality/complexity/ opacity of drug distribution" won’t abate any time soon, Grosslight tells investors in a research note. The analyst believes GoodRx will continue to serve a vital role in bringing transparency/consumerism to a historically "unshopable market."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GDRX:
